{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:46:28Z","timestamp":1791819988574,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijid.2026.109052","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:39:04Z","timestamp":1787269144000},"page":"109052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world effectiveness and impact of human papillomavirus vaccination in males: a comprehensive review"],"prefix":"10.1016","volume":"171","author":[{"given":"Andres F.","family":"Manrique","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekana K.","family":"Tadese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Rohlwing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Tota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Saraiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei (Vivian)","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.109052_bib0001","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijid.2026.109052_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2026.109052_bib0003","doi-asserted-by":"crossref","first-page":"918","DOI":"10.7326\/M21-3798","article-title":"Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018","volume":"175","author":"Rosenblum","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2026.109052_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e13108","article-title":"Global burden of HPV-related cancers in men: a systematic literature review","volume":"37","author":"Varga","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ijid.2026.109052_bib0006","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/pathogens13090809","article-title":"HPV and penile cancer: epidemiology, risk factors, and clinical insights","volume":"13","author":"Mannam","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.ijid.2026.109052_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fonc.2014.00009","article-title":"Human papillomavirus genotype prevalence in invasive penile cancers from a registry-based United States population","volume":"4","author":"Hernandez","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijid.2026.109052_bib0008","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1080\/21645515.2019.1600985","article-title":"HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection","volume":"15","author":"Timbang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2026.109052_bib0009","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1016\/S2214-109X(23)00305-4","article-title":"Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis","volume":"11","author":"Bruni","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijid.2026.109052_bib0010","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2480404","article-title":"Strategically striving to be more inclusive: a recommendation for gender-neutral human-papillomavirus vaccine policies","volume":"21","author":"Xu","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2026.109052_sbref0011","series-title":"HPV vaccine included in national immunization programme","year":"2019"},{"key":"10.1016\/j.ijid.2026.109052_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106335","article-title":"National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects","volume":"144","author":"Tsu","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.ijid.2026.109052_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103290","article-title":"Global HPV vaccination programs and coverage rates: a systematic review","volume":"84","author":"Han","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2026.109052_bib0014","unstructured":"World Health Organization. Human papillomavirus (HPV) vaccination coverage. WHO Immunization Data, https:\/\/immunizationdata.who.int\/global\/wiise-detail-page; [accessed February 13 2026]."},{"key":"10.1016\/j.ijid.2026.109052_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2026.109052_bib0016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0017","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/infdis\/jit018","article-title":"Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals","volume":"207","author":"Widdice","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0018","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/infdis\/jir644","article-title":"Genital transmission of human papillomavirus in recently formed heterosexual couples","volume":"204","author":"Burchell","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0019","first-page":"888","article-title":"Transmission of human papillomavirus in heterosexual couples","volume":"14","author":"Hernandez","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0020","article-title":"Transmission of genital human papillomavirus infection in couples: a population-based cohort study in rural China","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.109052_bib0021","doi-asserted-by":"crossref","unstructured":"Hisamoto K., Yamanaka M., Nomura M., Kanno N., Giuliano A.R., Wan K., et al. Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16\u201326 years in Japan: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. Epub ahead of print 2026. doi:10.1016\/S1473-3099(26)00291-4.","DOI":"10.1016\/S1473-3099(26)00291-4"},{"key":"10.1016\/j.ijid.2026.109052_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2425146","article-title":"Immunogenicity of the 9-valent human papillomavirus vaccine: post hoc analysis from five phase 3 studies","volume":"21","author":"Giuliano","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2026.109052_bib0023","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1080\/14760584.2022.2129615","article-title":"Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review","volume":"21","author":"Wang","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2026.109052_bib0024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/vaccines10091543","article-title":"Human papillomavirus vaccine impact and effectiveness in six high-risk populations: a systematic literature review","volume":"10","author":"Goodman","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ijid.2026.109052_bib0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0026","unstructured":"Schoonjans F. Relative risk, risk difference and odds ratio - computational notes. MedCalc, https:\/\/www.medcalc.org\/manual\/relative-risk-odds-ratio.php; [accessed July 28 2025]."},{"key":"10.1016\/j.ijid.2026.109052_bib0027","unstructured":"National Cancer Institute, Division of Cancer Control and Population Services. Annual percent change (APC) and confidence interval, https:\/\/surveillance.cancer.gov\/help\/joinpoint\/setting-parameters\/method-and-parameters-tab\/apc-aapc-tau-confidence-intervals\/estimate-average-percent-change-apc-and-confidence-interval; [accessed October 06 2025]."},{"key":"10.1016\/j.ijid.2026.109052_sbref0028","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 25: Assessing risk of bias in a non-randomized study","author":"Higgins","year":"2024"},{"key":"10.1016\/j.ijid.2026.109052_bib0029","article-title":"The risk of bias in non-randomized studies \u2013 of interventions, version 2 (ROBINS-I V2) assessment tool","author":"Sterne","year":"2025","journal-title":"Robins-I"},{"key":"10.1016\/j.ijid.2026.109052_bib0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jop.13091","article-title":"The impact of HPV vaccination on the prevalence of oropharyngeal cancer (OPC) in a hospital-based population: a cross-sectional study of patient\u2019s registry","volume":"50","author":"Katz","year":"2021","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.ijid.2026.109052_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093393","article-title":"Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men","volume":"9","author":"Swedish","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.109052_bib0032","doi-asserted-by":"crossref","first-page":"pkab086","DOI":"10.1093\/jncics\/pkab086","article-title":"Prevalence of oral human papillomavirus infection by number of vaccine doses among US adults","volume":"5","author":"Abel","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ijid.2026.109052_bib0033","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/cid\/ciab605","article-title":"Prevalence of oral human papillomavirus infection: impact of sex, race\/ethnicity, and vaccination status","volume":"74","author":"Berenson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/OLQ.0000000000001560","article-title":"Anal human papillomavirus prevalence among vaccinated and unvaccinated gay, bisexual, and other men who have sex with men in Canada","volume":"49","author":"Chambers","year":"2022","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/OLQ.0000000000000264","article-title":"Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth","volume":"42","author":"Kahn","year":"2015","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0036","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/LGT.0000000000000714","article-title":"Factors associated with anal high-grade intraepithelial lesions and carcinoma among young men who have sex with men and transgender women with HIV in Atlanta","volume":"27","author":"Loerinc","year":"2023","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0037","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/infdis\/jiaa306","article-title":"Vaccine effectiveness against prevalent anal and oral human papillomavirus infection among men who have sex with men\u2014United States, 2016\u20132018","volume":"222","author":"Meites","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0038","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/infdis\/jiab390","article-title":"Effectiveness of human papillomavirus (HPV) vaccination against penile HPV infection in men who have sex with men and transgender women","volume":"225","author":"Winer","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0039","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States","volume":"36","author":"Chaturvedi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2026.109052_bib0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ijc.34517","article-title":"Oral human papillomavirus (HPV) infection and HPV vaccination in an Australian cohort","volume":"153","author":"de Souza","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijid.2026.109052_bib0041","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2017.06.001","article-title":"Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure","volume":"146","author":"Lurie","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijid.2026.109052_bib0042","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1016\/j.vaccine.2019.08.052","article-title":"Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction","volume":"37","author":"Widdice","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.109052_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2530","article-title":"Trends in human papillomavirus\u2013associated cancers, demographic characteristics, and vaccinations in the US, 2001\u20132017","volume":"5","author":"Liao","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2026.109052_bib0044","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/OLQ.0000000000001235","article-title":"Impacts of human papillomavirus immunization programs on rates of anogenital warts in British Columbia, Canada, 2000 to 2017","volume":"47","author":"Lukac","year":"2020","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amepre.2021.06.026","article-title":"High-grade vulvar, vaginal, and anal precancers among U.S. adolescents and young adults after human papillomavirus vaccine introduction","volume":"62","author":"Mix","year":"2022","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.ijid.2026.109052_bib0046","article-title":"Trends in oropharyngeal cancer incidence among adult men and women in the United States from 2001 to 2018","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijid.2026.109052_bib0047","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1473-3099(20)30687-3","article-title":"Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study","volume":"21","author":"Chow","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7652","article-title":"Association of human papillomavirus vaccination with the incidence of squamous cell carcinomas of the anus in the US","volume":"8","author":"Berenson","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijid.2026.109052_bib0049","article-title":"Genital warts trends in Australian and overseas-born people in Australia: a cross-sectional trend analysis to measure progress towards control and elimination","volume":"16","author":"Khawar","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ijid.2026.109052_bib0050","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S1473-3099(21)00071-2","article-title":"Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004\u201318","volume":"21","author":"Chow","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0051","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/cid\/ciab171","article-title":"Significant declines in juvenile-onset recurrent respiratory papillomatosis following human papillomavirus (HPV) vaccine introduction in the United States","volume":"73","author":"Meites","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0052","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0053","first-page":"208","article-title":"A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program","volume":"217","author":"Novakovic","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0054","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/jpids\/piab016","article-title":"Juvenile-onset recurrent respiratory papillomatosis in the United States, epidemiology and HPV types-2015-2020","volume":"10","author":"Amiling","year":"2021","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.ijid.2026.109052_bib0055","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/jog.14345","article-title":"Human papillomavirus vaccination: good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India","volume":"46","author":"Bhatla","year":"2020","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ijid.2026.109052_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1544220","article-title":"Optimizing HPV vaccine effectiveness: impact of vaccination age and dose schedule on immunogenicity and cervical cancer prevention","volume":"13","author":"Rostami Varnousfaderani","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijid.2026.109052_bib0057","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1080\/21645515.2019.1625642","article-title":"Associations between HPV vaccination among women and their 11\u201314-year-old children","volume":"15","author":"Kornides","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2026.109052_bib0058","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2239085","article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review","volume":"19","author":"Ellingson","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2026.109052_bib0059","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.109052_bib0060","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2026.109052_bib0061","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.109052_bib0062","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/OLQ.0000000000001923","article-title":"Sexual behavior and perceived risk for oropharyngeal cancer among men who have sex with men: a psychometric scale validation","volume":"51","author":"Bennis","year":"2024","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijid.2026.109052_bib0063","unstructured":"CDC. Men who have sex with men (MSM), https:\/\/www.cdc.gov\/std\/treatment-guidelines\/msm.htm; [accessed July 31 2025]."},{"key":"10.1016\/j.ijid.2026.109052_bib0064","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s40615-022-01396-2","article-title":"Factors that predict HPV vaccination behavior among young men-who-have-sex-with-men in the greater Philadelphia Region","volume":"10","author":"Mann-Barnes","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"key":"10.1016\/j.ijid.2026.109052_bib0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13027-025-00649-z","article-title":"Shifting HPV-cancer burden: from cervical cancer to oropharyngeal cancer","volume":"20","author":"Volpi","year":"2025","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.ijid.2026.109052_bib0066","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus\u2013positive head and neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2026.109052_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/746769","article-title":"Estimating cancer latency times using a Weibull model","volume":"2014","author":"Nadler","year":"2014","journal-title":"Adv Epidemiol"},{"key":"10.1016\/j.ijid.2026.109052_bib0068","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/jnci\/djad009","article-title":"Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study","volume":"115","author":"Landy","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijid.2026.109052_bib0069","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ijc.70432","article-title":"Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time","volume":"159","author":"Yaksich","year":"2026","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijid.2026.109052_bib0072","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiz555","article-title":"Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses","volume":"221","author":"Markowitz","year":"2020","journal-title":"J Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:50:32Z","timestamp":1791816632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226006879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":69,"alternative-id":["S1201971226006879"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109052","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and impact of human papillomavirus vaccination in males: a comprehensive review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"109052"}}